Key studies published in 2019 highlight novel concepts regarding the pathogenesis of inflammatory bowel disease: the emerging role of host–microorganism interactions and the regional microbiota as disease drivers, and the identification of new therapeutic targets. These findings suggest new avenues for research and define important hallmarks for clinical diagnosis and therapy.
Rock the Cancer Warrior T-Shirt! Bold, comfy, and perfect for researchers, nurses, oncologists, and patients. Available in 10 colors—proceeds support cancer awareness. Wear your strength!…
Reflecting on Steve Jobs death, we examine his cancer journey and the evolution of treatments. What if he had today’s options?
Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of Londonon February 17, 2025 At the 2025 ASCO Genitourinary Cancers…
Exciting findings from the BREAKWATER study: encorafenib and cetuximab combination therapy improves treatment outcomes for patients with BRAF V600E-mutant metastatic colorectal cancer.
The Nivolumab CheckMate-274 trial reveals promising data on overall survival in muscle-invasive bladder cancer.
The FDA approves Adcetris in a new therapy for adults with relapsed Large B-cell Lymphoma, improving overall survival rates.
The FDA has recently approved a game-changing treatment for breast cancer patients. In this video, we break down the approval of datopotamab deruxtecan-dlnk,…
Learn about the game-changing EMBER-3 trial. Dive into the results of Imlunestrant, a groundbreaking SERD for ER+, HER2- Advanced Breast Cancer.
Explore the latest findings from a real-world data analysis on the effectiveness of immunotherapy in treating metastatic biliary tract cancer (mBTC) with spe…
Welcome to OncologyTube.com, where we bring you the latest in oncology research and treatment breakthroughs. In this video, we feature an insightful intervie…
